This study is for patients that have been diagnosed with ovarian cancer who are taking bevacizumab. This study is testing two investigational drugs called nelfinavir and hydroxychloroquine. "Investigational" means it has not been approved by the United States Food and Drug Administration (FDA) for the treatment of cancer. The primary purpose of this study is to see if these two medications in combination with bevacizumab are safe and effective in ovarian cancer. These drugs will be given by mouth. Participants in this study can expect to be in this study for 6 months for data collection, but may continue on the study medications longer if seeing benefit.

The purpose of the study is to evaluate the safety and how well the medication sotatercept works versus placebo in treating Heart Failure with a Preserved Ejection Fraction. The study will also look at information obtained from the tests performed as part of the study to see if subjects have improvement in symptoms of heart failure. Participation in this study will last approximately 26 months. During the study period subjects will be asked to attend regular study visits with the research coordinator. These visits will include such activities as blood tests, questionnaires, physical evaluation by a study doctor, a right heart catheterization with exercise, echocardiogram, and 6 minute hall walks. There will be 35 visits as part of participation in this clinical trial.

Participants will be randomized to either the treatment group (and receive the medication) or the control group (and not receive the medication). Subjects will have a 2:1 chance of receiving the study medication during their participation in the trial. The treatment assignment is determined by randomization, where a computer selects at random which treatment group you will be in (like drawing straws). Neither the subject, nor the blinded personnel will know which group subjects are in. Neither the subject nor the study doctor will decide what group subjects are assigned. Participants from the placebo group in CADENCE who enter HARMONIZE at Visit 9a will be randomized 1:1 to one of the active treatment groups. Participants from an active treatment group in CADENCE entering HARMONIZE after Visit 9a will be allocated to continue in the same treatment group (ie, sotatercept dose level) as in CADENCE.

Hearing loss is common, but many people don't realize they have it until years after it begins. This study will explore whether everyday speech and conversation can reveal early signs of hearing loss. In one part of the study, we will record conversations between participants and healthcare professionals to study how speech patterns may differ in people with and without hearing loss. In another part, we will review transcripts from past clinic visits to see if certain patterns, like pauses or asking for things to be repeated, are linked to hearing problems. The goal is to develop tools that can help identify hearing loss earlier and more easily, using conversations that happen naturally during clinic visits.

We are testing a 2D system designed to help people with Parkinson's disease practice their speech. In this study, participants will speak with a virtual character, called an embodied conversational agent, using a laptop. Our goal is to see if this technology is helpful and easy to use for people with Parkinson's disease to use. This research will help us learn whether using virtual characters at home could support long-term speech improvements.